In light of these developments, this review aims to critically analyze the clinical and molecular efficacy of venetoclax in NPM1-mutated AML, with a particular focus on MRD-guided discontinuation strategies and their potential to redefine long-term disease management. This evidence concerns the gene NPM1 and acute myeloid leukemia.